August 23, 2010 - A new, rapid method of labeling peptides with a fluorine-18 (F-18) positron-emission tomography (PET) radiotracer is being evaluated.
Immunomedics Inc. and GE Healthcare announced they have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method.
Immunomedics developed a rapid, stable, and efficient way of labeling peptides with F-18 by first conjugating the radioisotope with aluminum. This is the first method of binding F-18 to peptides via an aluminum conjugate. F-18 labeled peptides have been shown to be stable enough to produce quality PET images of receptor-expressing tumors in animals and in pretargeting studies using a human colorectal cancer model.
Terms of the agreement were not disclosed, but GE Healthcare will fund all costs related to the collaboration.
For more information: www.immunomedics.com
October 30, 2026 
